The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Treatment of anxiety disorders
Open accessAbstract
Anxiety disorders (generalized anxiety disorder, panic disorder/agoraphobia, social anxiety disorder, and others) are the most prevalent psychiatric disorders, and are associated with a high burden of illness. Anxiety disorders are often underrecognized and undertreated in primary care. Treatment is indicated when a patient shows marked distress or suffers from complications resulting from the disorder. The treatment recommendations given in this article are based on guidelines, meta-analyses, and systematic reviews of randomized controlled studies. Anxiety disorders should be treated with psychological therapy, pharmacotherapy, or a combination of both. Cognitive behavioral therapy can be regarded as the psychotherapy with the highest level of evidence. First-line drugs are the selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Benzodiazepines are not recommended for routine use. Other treatment options include pregabalin, tricyclic antidepressants, buspirone, moclobemide, and others. After remission, medications should be continued for 6 to 12 months. When developing a treatment plan, efficacy, adverse effects, interactions, costs, and the preference of the patient should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this heterogeneity may explain why a significant proportion of individuals do not respond to first line therapy 5 .”
From The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, anxiety and related disorders are not only frequently comorbid, but each is also quite heterogeneous”
From The clinical characterization of the adult patient with an anxiety or related disorder aimed at personalization of management (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Selective serotonin (5-HT) reuptake inhibitors (SSRIs), including for example (es)citalopram, sertraline, fluoxetine are currently first-line drug treatment options for most anxiety disorders as they are proposed to have a better benefit/risk ratio than any other form of current pharmacotherapy (Bandelow, Michaelis, & Wedekind, 2017).”
From Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders (2019) · cites this paper as Bandelow, Michaelis, & Wedekind, 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, after exposure therapy completion, many patients experience a return of anxiety symptoms (9,12).”
From I Doubt It Is Safe: A Meta-analysis of Self-reported Intolerance of Uncertainty and Threat Extinction Training (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the adverse side‐effects of antidepressants and anti‐anxiety (anxiolytic) medications remain to be fully illustrated. 72 , 73 , 74”
From Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review (2023) · cites this paper as [74]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Epidemiology of anxiety disorders in the 21st century
Bandelow, B., & Michaelis, S. (2015) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2015.17.3/bbandelow · Cited by 2,079
Self-citationRegier, D. A. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820140007001 · Cited by 1,999
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Research works printed but not linked: 13
- Bandelow B., 2003, Handbook on Depression and Anxiety. New York, NY: M Dekker, 49
- Wittchen HU., 2002, J Clin Psychiatry., 63, 24
- Bandelow B., 2017, CNS Spectr., 1
- Alonso J., 2004, Acta Psychiatr Scand Suppl., 28
- Bradwejn J., 1993, Can J Psychiatry., 38, S109
- Livingston MG., 1994, Br J Hosp Med., 51, 281
- Nelson J., 1999, Can J Clin Pharmacol., 6, 69
- Bandelow B., 2014, Dtsch Arztebl Int., 111, 473
- Berney P., 2008, Psychopharmacol Bull., 41, 39
- Ipser JC., 2009, Cochrane Database Syst Rev., CD005170
- Hetrick SE., 2012, Cochrane Database Syst Rev., 11, CD004851
- James AC., 2015, Cochrane Database Syst Rev., CD004690
- World Health Organization., 1991, ICD-10 Chapter V (F) Classification of Mental and Behvioural Disorders: Clinical Descriptions and Diagnostic Guidelines. “Blue Book” Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organization;
Cited by
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C. O., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., et al. (2021) · Neurology International · doi:10.3390/neurolint13030038 · Cited by 440
The Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
The prefrontal cortex, pathological anxiety, and anxiety disorders
Kenwood, M. M., Kalin, N. H., & Barbas, H. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01109-z · Cited by 312
Inhibition in the amygdala anxiety circuitry
Babaev, O., Piletti Chatain, C., & Krueger-Burg, D. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0063-8 · Cited by 308
Metadata
- Authors
- Bandelow, B., Michaelis, S., & Wedekind, D.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Bandelow, Borwin
- Venue
- Dialogues in Clinical Neuroscience
- Publisher
- Informa UK Limited
- Published
- 2017-06-30
- Volume
- 19
- Issue
- 2
- Pages
- 93-107
- ISSN
- 1294-8322 (ISSN-L)
- 1958-5969
- PMC
- PMC5573566
- OpenAlex
- W2982634790
- Cited by
- 811
- References
- 106
- Citations by year
- 2026: 78 · 2025: 116 · 2024: 157 · 2023: 132 · 2022: 115 · 2021: 96 · 2020: 59 · 2019: 41 · 2018: 11 · 2017: 2
- FWCI
- 39.98
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Dialogues in Clinical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by-nc-nd)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- anxiety disorders, generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder, cognitive behavioral therapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, benzodiazepines, pregabalin, tricyclic antidepressants, buspirone, moclobemide, pharmacotherapy, psychotherapy, primary care, treatment guidelines
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Humans, Psychotherapy, Anti-Anxiety Agents, Cognitive Behavioral Therapy, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of anxiety disorders. https://app.cochat.ai/papers/10.31887/dcns.2017.19.2/bbandelow
- The paper
- Bandelow, B., Michaelis, S., & Wedekind, D. (2017). Treatment of anxiety disorders. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2017.19.2/bbandelow
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.